• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C1q 使流感血凝素茎结合抗体能够阻止病毒附着,并拓宽了抗体逃逸的范围。

C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire.

机构信息

Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.

Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

出版信息

Sci Immunol. 2024 Mar 22;9(93):eadj9534. doi: 10.1126/sciimmunol.adj9534.

DOI:10.1126/sciimmunol.adj9534
PMID:38517951
Abstract

Antigenic drift, the gradual accumulation of amino acid substitutions in the influenza virus hemagglutinin (HA) receptor protein, enables viral immune evasion. Antibodies (Abs) specific for the drift-resistant HA stem region are a promising universal influenza vaccine target. Although anti-stem Abs are not believed to block viral attachment, here we show that complement component 1q (C1q), a 460-kilodalton protein with six Ab Fc-binding domains, confers attachment inhibition to anti-stem Abs and enhances their fusion and neuraminidase inhibition. As a result, virus neutralization activity in vitro is boosted up to 30-fold, and in vivo protection from influenza PR8 infection in mice is enhanced. These effects reflect increased steric hindrance and not increased Ab avidity. C1q greatly expands the anti-stem Ab viral escape repertoire to include residues throughout the HA, some of which cause antigenic alterations in the globular region or modulate HA receptor avidity. We also show that C1q enhances the neutralization activity of non-receptor binding domain anti-SARS-CoV-2 spike Abs, an effect dependent on spike density on the virion surface. These findings demonstrate that C1q can greatly expand Ab function and thereby contribute to viral evolution and immune escape.

摘要

抗原漂移是流感病毒血凝素(HA)受体蛋白中氨基酸取代的逐渐积累,使病毒能够逃避免疫。针对漂移抗性 HA 茎区的抗体(Abs)是一种有前途的通用流感疫苗靶点。尽管人们认为针对茎区的 Abs 不会阻止病毒附着,但在这里我们表明,补体成分 1q(C1q),一种具有六个 Ab Fc 结合结构域的 460 千道尔顿蛋白,赋予针对茎区的 Abs 附着抑制作用,并增强其融合和神经氨酸酶抑制作用。结果,体外病毒中和活性提高了 30 倍,体内对流感 PR8 感染的保护作用增强。这些效应反映了增加的空间位阻,而不是增加的 Ab 亲和力。C1q 极大地扩展了针对茎区的 Ab 病毒逃逸谱,包括整个 HA 中的残基,其中一些残基在球形区域引起抗原改变或调节 HA 受体亲和力。我们还表明,C1q 增强了非受体结合域抗 SARS-CoV-2 刺突 Abs 的中和活性,这种效应依赖于病毒表面刺突密度。这些发现表明,C1q 可以极大地扩展 Ab 的功能,从而促进病毒进化和免疫逃避。

相似文献

1
C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire.C1q 使流感血凝素茎结合抗体能够阻止病毒附着,并拓宽了抗体逃逸的范围。
Sci Immunol. 2024 Mar 22;9(93):eadj9534. doi: 10.1126/sciimmunol.adj9534.
2
Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.血凝素茎部反应性抗体通过空间位阻干扰流感病毒神经氨酸酶活性。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01526-18. Print 2019 Feb 15.
3
Immune Escape Adaptive Mutations in Hemagglutinin Are Responsible for the Antigenic Drift of Eurasian Avian-Like H1N1 Swine Influenza Viruses.免疫逃逸适应性突变使欧亚类禽 H1N1 猪流感病毒发生抗原漂移。
J Virol. 2022 Aug 24;96(16):e0097122. doi: 10.1128/jvi.00971-22. Epub 2022 Aug 2.
4
Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.甲型流感病毒神经氨酸酶和血凝素的突变赋予了对广泛中和血凝素茎抗体的抗性。
J Virol. 2019 Jan 4;93(2). doi: 10.1128/JVI.01639-18. Print 2019 Jan 15.
5
HA gene amino acid mutations contribute to antigenic variation and immune escape of H9N2 influenza virus.HA 基因氨基酸突变有助于 H9N2 流感病毒的抗原变异和免疫逃逸。
Vet Res. 2022 Jun 15;53(1):43. doi: 10.1186/s13567-022-01058-5.
6
Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.补体成分C1q根据流感病毒血凝素特异性抗体的精细抗原特异性和重链同种型增强其生物活性。
J Virol. 2002 Feb;76(3):1369-78. doi: 10.1128/jvi.76.3.1369-1378.2002.
7
Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice.一种针对 2009 年大流行 H1N1 病毒血凝素的人源单克隆抗体产生的抗体压力,促使病毒在小鼠中出现毒力增强。
mBio. 2012 May 29;3(3). doi: 10.1128/mBio.00120-12. Print 2012.
8
Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.H5N1 流感病毒血凝素的构象稳定性影响对广谱中和茎部抗体的敏感性。
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00247-18. Print 2018 Jun 15.
9
Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies.上位性降低了甲型流感病毒逃避茎结合抗体的适应代价。
Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2208718120. doi: 10.1073/pnas.2208718120. Epub 2023 Apr 17.
10
Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.鉴定缺乏血凝抑制活性的新型交叉反应性乙型流感病毒血凝素头部特异性抗体。
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01185-20.

引用本文的文献

1
Antigenic drift expands influenza viral escape pathways from recalled humoral immunity.抗原漂移扩展了流感病毒逃避回忆性体液免疫的途径。
Immunity. 2025 Mar 11;58(3):716-727.e6. doi: 10.1016/j.immuni.2025.02.006. Epub 2025 Feb 28.
2
Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infection.流感病毒疫苗接种或感染后针对血凝素(HA)的多克隆IgG反应的结构图谱分析
mBio. 2025 Mar 12;16(3):e0203024. doi: 10.1128/mbio.02030-24. Epub 2025 Feb 6.
3
Influenza A Virus H7 nanobody recognizes a conserved immunodominant epitope on hemagglutinin head and confers heterosubtypic protection.
甲型流感病毒H7纳米抗体识别血凝素头部保守的免疫显性表位并提供异源亚型保护。
Nat Commun. 2025 Jan 9;16(1):432. doi: 10.1038/s41467-024-55193-y.
4
Modulation of B cell receptor activation by antibody competition.通过抗体竞争对B细胞受体激活的调节。
bioRxiv. 2024 Nov 21:2024.11.18.624200. doi: 10.1101/2024.11.18.624200.
5
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.评估2组流感血凝素稳定化茎部纳米颗粒疫苗的1期剂量递增试验。
NPJ Vaccines. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0.
6
Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or Infection.流感病毒疫苗接种或感染后针对血凝素(HA)的多克隆IgG反应的结构图谱
bioRxiv. 2024 Jul 11:2024.07.08.601940. doi: 10.1101/2024.07.08.601940.
7
Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays.重组 OC43 SARS-CoV-2 刺突替代病毒:一种用于 SARS-CoV-2 中和测定的改良 BSL-2 替代病毒。
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2310421121. doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8.